Northern Trust Corp Invests $1.79 Million in Inhibrx, Inc. (NASDAQ:INBX)

Northern Trust Corp bought a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 116,104 shares of the company's stock, valued at approximately $1,788,000. Northern Trust Corp owned 0.80% of Inhibrx at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Exchange Traded Concepts LLC bought a new position in shares of Inhibrx in the fourth quarter worth approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Inhibrx in the 4th quarter valued at approximately $348,000. China Universal Asset Management Co. Ltd. purchased a new position in Inhibrx during the 4th quarter worth approximately $47,000. Rhumbline Advisers purchased a new position in shares of Inhibrx during the 4th quarter valued at approximately $228,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Inhibrx during the 4th quarter valued at approximately $53,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a report on Thursday, May 15th.

Inhibrx Stock Down 1.4%

INBX traded down $0.19 on Friday, reaching $13.56. The company's stock had a trading volume of 76,321 shares, compared to its average volume of 118,067. The company has a market capitalization of $196.29 million and a price-to-earnings ratio of 0.12. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The stock has a 50 day moving average of $12.40 and a two-hundred day moving average of $13.45.

Inhibrx (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). As a group, analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.